<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E89C5F6C-3EB1-417F-943E-127C327DAEDD"><gtr:id>E89C5F6C-3EB1-417F-943E-127C327DAEDD</gtr:id><gtr:firstName>Eleanor</gtr:firstName><gtr:surname>Barnes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/77FAD11B-305D-4975-BE4B-56B52E964A0D"><gtr:id>77FAD11B-305D-4975-BE4B-56B52E964A0D</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:surname>Collier</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9B847ED0-D2B1-494D-A537-43DA52723D39"><gtr:id>9B847ED0-D2B1-494D-A537-43DA52723D39</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Klenerman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0701694"><gtr:id>E862089D-513E-424F-A925-D70AED8C04CC</gtr:id><gtr:title>A novel strategy for the therapeutic vaccination of hepatitis C Virus using adenoviral vectors</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701694</gtr:grantReference><gtr:abstractText>Hepatitis C virus currently infects 180 million people world-wide and 1% of the population in the United Kingdom. The majority of people that become infected do not clear the virus from the body and approximately 20% of people will develop severe liver scarring (cirrhosis) and may require liver transplantation. One of the main reasons why people do not get rid of hepatitis C is that the immune system does not see and attack the virus.
 The current best treatment is called combination therapy. This treatment has many side effects, involves weakly injections and has to be given for a year in many patients. At the end of this treatment less than half of patients get rid of the virus. Our aim is to develop a vaccine that is given to patients before or during combination therapy so that more patients will get rid of the virus. To do this we have developed a vaccine that we hope will stimulate the immune system of patients. 
This vaccine is made from a part of the common cold virus-called adenovirus-and we have put a part of the hepatitis C virus into the cold virus. The adenovirus acts like a carrier to deliver the part of the hepatitis C virus and hopefully turn on the immune system. Importantly, the cold virus and the part of the hepatitis C virus have been altered to that they cannot replicate and themselves cause an infection. However, many people have previously been infected with the cold virus and because of this their immune system may try to attack our vaccine. To get around this problem we are going to use two unusual types of carrier cold vaccines that will not have infected people before. One of these is a cold virus that usually infects only chimpanzees. We are going to test these vaccines in 2007-2008 in people without hepatitis C. In this project we want to give these vaccines to patients with hepatitis C to see if we can turn on the immune system to attack the virus.</gtr:abstractText><gtr:technicalSummary>Introduction/aims: Hepatitis C virus (HCV) infection is a world-wide epidemic. HCV genotype-1 is the commonest genotype in the UK and is resistant to therapy with current gold-standard treatment, pegylated-interferon and ribavirin, in the majority of patients. This treatment is prolonged, expensive and unpleasant. HCV protease and polymerase inhibitors are in development, however early viral resistance and side-effects appear problematic. In patients who spontaneously eradicate virus, effective cellular immunity plays a crucial role, whereas in persistent infection HCV specific T-cell responses are weak. Our aim is to develop a safe, effective, therapeutic T-cell vaccine for HCV that will prime or boost antiviral T-cell responses. These may contribute to control of viremia. We hypothesise that this strategy may be more effective in the setting of a reduced viral load and anticipate that in the future this would be given before or in conjunction with HCV antivirals to improve sustained virological response rates. 

Methodology/outcomes: In this proof of concept study our primary outcomes will be safety, tolerability and immunogenicity using adenoviral vectors in HCV infected patients with high and low viral loads. Effect on HCV viral load will be a secondary end-point. Adenoviral vectors are highly immunogenic but immunogenicity against the vectors is an issue. To circumvent this problem, we will use a human adenoviral vector rarely encountered (Ad6) and a simian adenoviral vector (AdCh3) in a heterologous prime/boost regimen. The immunogen will be the non-structural HCV proteins NS3-NS5b, genetically mutated to inactivate the HCV polymerase, encoding multiple CD4+ and CD8+ T-cell epitopes. We are currently testing this regimen in healthy volunteers. 

Experimental design/techniques: Vaccination will comprise 2 priming injections 4 weeks apart followed by a boost 8 weeks later. We will perform a sequential dose escalation study in 2 groups of patients (i) low viral load patients: These will be 12 weeks into combination therapy and have a 2 log decline in HCV load, or undetectable HCV-RNA and (ii) high viral load patients: these will have untreated chronic infection. State of the art immunological techniques will assess the quantity and quality of HCV specific T-cell responses before and after vaccination. These include IFN-? ELISpot, HLA class-I and class-II tetramer technology, and multiparametric assessment of cytokine secretion. 

Application/Exploitation: These aims will be achieved together with an industrial partner (Okairos). If proof of concept is demonstrated we will be in an excellent position to take this technology into clinical trials of efficacy.</gtr:technicalSummary><gtr:fund><gtr:end>2012-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>250000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Okairos</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>industry partner collaboration-Okairos</gtr:description><gtr:id>1753C06C-8847-4710-9F25-A58BA604A2F4</gtr:id><gtr:impact>This collaboration is essential to meet the aims of the project</gtr:impact><gtr:partnerContribution>production and supply of HCV adenoviral and MVA viral vectored vaccines</gtr:partnerContribution><gtr:piContribution>We have embarked on a HCV vaccine research program in healthy volunteers and HCV infected patients. We have designed three phase I clinical studies, are recruiting and caring for the patients, and are performing the immunology assays and data analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Okairos</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Biopharmaceutical company-Okairos</gtr:description><gtr:id>7CB94B70-F3C6-4C12-A19A-1FDFAB63829F</gtr:id><gtr:impact>Plenary session presentation at American liver meeting 2009. An MRC experimental medicine award to assess the same vaccine in HCV infected patients in an academic led study.</gtr:impact><gtr:partnerContribution>Okairos have made the adenoviral vaccine vectors required for our phase I clinical studies and have helped in project management</gtr:partnerContribution><gtr:piContribution>We have embarked on a HCV vaccine research program in healthy volunteers and HCV infected patients. We have designed three phase I clinical studies, are recruiting and caring for the patients, and are performing the immunology assays and data analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Jenner Institute</gtr:department><gtr:description>Jenner Institute</gtr:description><gtr:id>2F761CF9-ABA9-4887-9E5B-4E9F64A57696</gtr:id><gtr:impact>Publication and sharing of expertise</gtr:impact><gtr:partnerContribution>Expertise in vaccine development</gtr:partnerContribution><gtr:piContribution>HCV vaccine development</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>News letter-viral hepatitis</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C83030DA-7D07-434C-90CC-CEB848AD19D3</gtr:id><gtr:impact>This study was presented in a newsletter on viral hepatitis that is sent to healthcare professionals in Europe.

N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture series</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>20190AAE-983D-4A01-B743-20A0A2C1CCF2</gtr:id><gtr:impact>As Above

Further dissemination to the public resulted with an invitations to write for public news letters</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>public lecture Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>77A6F9ED-FFA0-4FEE-AA4C-191B3C111EB6</gtr:id><gtr:impact>40 patients and interested health care workers attended a public lecture (held every 6 months) which sparked questions, discussions and resulted in us recruiting lay people to our research group.

Resulted in patient recruitment to our study.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Liver Congress, EASL 2017 (Barcelona)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7F9EB49C-F788-41DC-AE2C-0AB08150400F</gtr:id><gtr:impact>Registry grant presentation&amp;quot; Thursday 14 April 2016 from 12:00 to 13:30.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture series to HCV infected patients</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>23E0B2AC-D21B-4359-B2DD-5775C5E4B5E5</gtr:id><gtr:impact>50 patients and interested health care professionals attended.

Initial talk has turned into a 6 monthly rolling programme.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dissemination of information about Oxford HCV vaccine programme</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A4E20B7A-8DF8-4464-B1D4-981689B11E77</gtr:id><gtr:impact>We wrote an article (in press) that is distributed to both health professionals and patients about the HCV Oxford vaccine programme,

Publication-in press</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>94199</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>NIHR Oxford Biomedical Research Centre-FSF funding</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Trust</gtr:fundingOrg><gtr:id>E9B48BD8-C9FB-4334-8FBC-812B8B7E1C0C</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>208037</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome trust NDM studentship</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>FE41C750-E4F6-49AA-ADF0-6104BCB9C7A6</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>NIHR Oxford Biomedical Research Centre-cohorts</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Trust</gtr:fundingOrg><gtr:id>0223B8FF-6A5D-4C82-B6E8-EDAD64F4537A</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>208000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Biomedical Sciences Training Fellowship; Biological role of IFN-lambda-3</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>BB63ED82-EEB1-4AB1-8D6E-39852627A4E5</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We have assessed a novel HCV vaccine in healthy volunteers we have shown to be safe and highly immunogenic.</gtr:description><gtr:id>D28D6657-10FF-4A7A-BCFA-485E908B5D66</gtr:id><gtr:impact>Further funding (MRC experimental medicine award) to assess the same vaccine in HCV infected patients has been obtained</gtr:impact><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>An adenoviral vectored vaccine for HCV infection</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This is state of the art database that we instigated in 2009 to collect clinical information on HCV patients for a longitudinal cohort study of HCV. This will inform not only natural history, but also identify markers of HCV progression and aid recruittment of studies of experimental medicine.</gtr:description><gtr:id>6F90CE0E-0752-4486-B5E1-BB90E2AE9B5A</gtr:id><gtr:impact>No impacts yet, though this tool has been very recently conceived</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A state of the art Cellma HCV database to establish a HCV patient cohort</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E4F608C7-7C87-408E-83F7-810274CF732B"><gtr:id>E4F608C7-7C87-408E-83F7-810274CF732B</gtr:id><gtr:title>Adenoviral Vector Vaccination Induces a Conserved Program of CD8(+) T Cell Memory Differentiation in Mouse and Man.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c5790411e8c5d561eee2f8a97bfbd48e"><gtr:id>c5790411e8c5d561eee2f8a97bfbd48e</gtr:id><gtr:otherNames>Bolinger B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/359D7499-4C1B-4112-B4B8-6D9631BEFBDE"><gtr:id>359D7499-4C1B-4112-B4B8-6D9631BEFBDE</gtr:id><gtr:title>Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d70dc7bb49a750d51b5f50e44caa910f"><gtr:id>d70dc7bb49a750d51b5f50e44caa910f</gtr:id><gtr:otherNames>Kelly C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/613B99C0-3554-4A51-BFFE-9B91E8FB60B3"><gtr:id>613B99C0-3554-4A51-BFFE-9B91E8FB60B3</gtr:id><gtr:title>Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e878b1af1aa4bdbd1966248e20dba0a"><gtr:id>1e878b1af1aa4bdbd1966248e20dba0a</gtr:id><gtr:otherNames>Colloca S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D2D0C98E-35E4-42E2-86D0-A4AD47D69843"><gtr:id>D2D0C98E-35E4-42E2-86D0-A4AD47D69843</gtr:id><gtr:title>Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d70dc7bb49a750d51b5f50e44caa910f"><gtr:id>d70dc7bb49a750d51b5f50e44caa910f</gtr:id><gtr:otherNames>Kelly C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/51A46A8C-10D4-46C1-9458-BE29765C5832"><gtr:id>51A46A8C-10D4-46C1-9458-BE29765C5832</gtr:id><gtr:title>Screening and treatment for hepatitis C: a balanced perspective.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D9AC622A-3204-4ABD-9189-168F5F52B83F"><gtr:id>D9AC622A-3204-4ABD-9189-168F5F52B83F</gtr:id><gtr:title>Interferon lambdas: the next cytokine storm.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d70dc7bb49a750d51b5f50e44caa910f"><gtr:id>d70dc7bb49a750d51b5f50e44caa910f</gtr:id><gtr:otherNames>Kelly C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0535FBD4-1A81-45E7-B3AF-D150BF09BBB7"><gtr:id>0535FBD4-1A81-45E7-B3AF-D150BF09BBB7</gtr:id><gtr:title>Co-Administration of Chimpanzee Adenoviral Vectors of Different Serotypes, for the Prevention of HCV and HIV Co-Infection</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c8c50e991e0204bf5c7c8bf907bbb348"><gtr:id>c8c50e991e0204bf5c7c8bf907bbb348</gtr:id><gtr:otherNames>Hartnell F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FB883A7C-C3C9-4135-B47F-0857C20C82D1"><gtr:id>FB883A7C-C3C9-4135-B47F-0857C20C82D1</gtr:id><gtr:title>HCV T Cell Re-Vaccination Strategies using Simian Adeno and MVA Viral Vectors to Enhance and Maintain Anti-Viral Immunity</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c8c50e991e0204bf5c7c8bf907bbb348"><gtr:id>c8c50e991e0204bf5c7c8bf907bbb348</gtr:id><gtr:otherNames>Hartnell F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701694</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>